Salsola pollen allergy immunotherapy - ALK-Abello

Drug Profile

Salsola pollen allergy immunotherapy - ALK-Abello

Alternative Names: AVANZ® Salsola; Polen de salsola kali immunotherapy- ALK-Abello; Salsola kali pollen allergy immunotherapy - ALK-Abello; Thistle pollen allergy immunotherapy - ALK-Abello

Latest Information Update: 09 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ALK-Abello
  • Class Allergens; Allergy immunotherapies; Antiallergics; Tree pollen allergy immunotherapies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Allergic rhinoconjunctivitis

Most Recent Events

  • 09 Jun 2017 No recent reports on development identified - Phase-II for Allergic rhinoconjunctivitis in Spain (SC)
  • 01 Dec 2014 ALK-Abello completes a phase II trial in Allergic rhinoconjunctivitis (with or without asthma) in Spain (NCT02065856)
  • 16 Jun 2014 ALK-Abello completes enrolment in its phase II trial for Allergic rhinoconjunctivitis (with or without asthma) in Spain (NCT02065856)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top